口服抗高血压药治疗妊娠期慢性高血压疗效与安全性的网络荟萃分析
随机对照试验汇总显示,阿替洛尔显著增加小于胎龄儿风险,硝苯地平和甲基多巴显著降低严重高血压和胎盘早剥发生率,但子痫前期风险各药无显著差异。
要点
- 阿替洛尔与小于胎龄儿风险显著升高相关,排名最差。
- 硝苯地平和甲基多巴可显著降低严重高血压及胎盘早剥风险。
- 各抗高血压药对子痫前期风险无显著影响。
核心结论
- 阿替洛尔与小于胎龄儿风险显著增加相关。
- 硝苯地平和甲基多巴可显著降低严重高血压发生率,但子痫前期风险各药相似。
研究设计与样本
- 纳入报告抗高血压药对慢性高血压女性围产期结局影响的随机对照试验和队列研究。
- 主要结局为子痫前期和小于胎龄儿风险,采用频率学派网络荟萃随机效应模型,主要分析基于随机对照试验。
主要发现
- 随机对照试验汇总显示,无药物显著影响子痫前期发生率。
- 与未用药相比,硝苯地平(OR 0.27,95%CI 0.14-0.55)、甲基多巴(OR 0.31,95%CI 0.17-0.56)、酮色林(OR 0.29,95%CI 0.09-0.90)和吲哚洛尔(OR 0.17,95%CI 0.05-0.55)显著降低严重高血压发生率。
- 硝苯地平和甲基多巴与显著降低的胎盘早剥率相关(OR 0.29,95%CI 0.15-0.58;OR 0.23,95%CI 0.11-0.46)。
- 剖宫产、围产期死亡、早产和分娩孕周无显著差异。
关键数值与推荐
- 阿替洛尔与小于胎龄儿风险显著升高相关(OR 26.00,95%CI 2.61-259.29)。
- 硝苯地平、甲基多巴、酮色林、吲哚洛尔降低严重高血压的OR分别为0.27、0.31、0.29、0.17。
- 硝苯地平和甲基多巴降低胎盘早剥的OR分别为0.29和0.23。
临床怎么用
- 妊娠期慢性高血压治疗中应避免使用阿替洛尔,因其显著增加小于胎龄儿风险。
- 硝苯地平和甲基多巴可考虑用于降低严重高血压和胎盘早剥风险。
- 药物选择对子痫前期风险无显著影响,需个体化决策。
局限性
- 证据可信度评估考虑了研究内偏倚、研究间偏倚、间接性、不精确性、异质性和不一致性。
- 未来需大规模试验指导抗高血压治疗选择和孕期目标血压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE DATA: Chronic hypertension is associated with adverse perinatal outcomes, although the optimal treatment is unclear. The aim of this network metaanalysis was to simultaneously compare the efficacy and safety of antihypertensive agents in pregnant women with chronic hypertension. STUDY: Medline, Scopus, CENTRAL, Web of Science, Clinicaltrials.gov, and Google Scholar databases were searched systematically from inception to December 15, 2019. Both randomized controlled trials and cohort studies were held eligible if they reported the effects of antihypertensive agents on perinatal outcomes among women with chronic hypertension. STUDY APPRAISAL AND SYNTHESIS METHODS: The primary outcomes were preeclampsia and small-for-gestational-age risk. A frequentist network metaanalytic random-effects model was fitted. The main analysis was based on randomized controlled trials. The credibility of evidence was assessed by taking into account within-study bias, across-studies bias, indirectness, imprecision, heterogeneity, and incoherence. RESULTS: Twenty-two studies (14 randomized controlled trials and 8 cohorts) were included, comprising 4464 women. Pooling of randomized controlled trials indicated that no agent significantly affected the incidence of preeclampsia. Atenolol was associated with significantly higher risk of small-for-gestational age compared with placebo (odds ratio, 26.00; 95% confidence interval, 2.61-259.29) and is ranked as the worst treatment (P-score=.98). The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0.27; 95% confidence interval, 0.14-0.55), methyldopa (odds ratio, 0.31; 95% confidence interval, 0.17-0.56), ketanserin (odds ratio, 0.29; 95% confidence interval, 0.09-0.90), and pindolol (odds ratio, 0.17; 95% confidence interval, 0.05-0.55) were administered compared with no drug intake. The highest probability scores were calculated for furosemide (P-score=.86), amlodipine (P-score=.82), and placebo (P-score=.82). The use of nifedipine and methyldopa were associated with significantly lower placental abruption rates (odds ratio, 0.29 [95% confidence interval, 0.15-0.58] and 0.23 [95% confidence interval, 0.11-0.46], respectively). No significant differences were estimated for cesarean delivery, perinatal death, preterm birth, and gestational age at delivery. CONCLUSION: Atenolol was associated with a significantly increased risk for small-for-gestational-age infants. The incidence of severe hypertension was significantly lower when nifedipine and methyldopa were administered, although preeclampsia risk was similar among antihypertensive agents. Future large-scale trials should provide guidance about the choice of antihypertensive treatment and the goal blood pressure during pregnancy.
引用
- Bellos I, Pergialiotis V, Papapanagiotou A, et al. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol. 2020. PMID: 32199925. doi:10.1016/j.ajog.2020.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。